Effective anti-tumour immunity in humans has been associated with the presence of T cells
directed at cancer neoantigens 1 , a class of HLA-bound peptides that arise from tumour-…

Recent studies have reported the protective efficacy of both natural 1 and vaccine-induced
2 , 3 , 4 , 5 , 6 – 7 immunity against challenge with severe acute respiratory syndrome …

The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top …

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
may be required to end the coronavirus disease 2019 (COVID-19) pandemic 1 , 2 , 3 , 4 …

An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global …

The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1)
eradication strategies 1 , 2 , 3 , 4 , 5 . However, it remains unclear when and where …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1 infection.
Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific broadly …

Personal neoantigen vaccines have been envisioned as an effective approach to induce,
amplify and diversify antitumor T cell responses. To define the long-term effects of such a …